Ann: Presentation of BIT225-009 HIV-1 Phase 2 Data, page-926

We agree it is a new assay, beyond that not much. BIT doesn't have any clinical outcome data from their trial (it was only a 12 week trial) so they don't know what any of the cell associated data means for the patients health. Let's say they see virus in macrophages goes down, but goes up in T-cells what does that mean for the patient? The reason assays of virus in the blood mean something is lower levels of virus in the blood has been shown to result in longer patient life and better control of the virus over time. It is a validated proxy for clinical utility. BIT's novel assay is not a valid proxy for any clinical utility as it has not been validated against any clinical outcome.

Once again people are repeating the lie that current antiretrovirals don't work in macrophages. This is 100% false and is not something BIT has ever claimed. What current HIV drugs can't do is clear HIV from all macrophages, but again BIT doesn't have any data that BIT225 does either.